[Mycophenolate mofetil maintenance therapy in lupus nephritis]

Area of Science:

• Nephrology
• Immunology
• Rheumatology

Background:

• Lupus nephritis is a severe complication of systemic lupus erythematosus (SLE).
• Maintenance therapy is crucial for sustained remission and preventing disease flares.
• Assessing novel therapeutic options for lupus nephritis is an ongoing clinical need.

Purpose of the Study:

• To evaluate the clinical efficacy of mycophenolate mofetil (MMF) as maintenance therapy for lupus nephritis.
• To assess changes in immunological parameters during MMF maintenance therapy.
• To determine the safety and tolerance of MMF in this patient population.

Main Methods:

• A cohort of 7 patients with biopsy-proven lupus nephritis and achieved remission were enrolled.
• Patients received MMF (1000 mg daily) for 3 months following induction therapy.
• Clinical, immunological parameters, and drug tolerance were monitored at baseline and at 1 and 3 months.

Main Results:

• MMF therapy led to a significant decrease in the SLE Disease Activity Index (SLEDAI).
• Proteinuria reduction and renal function improvements were maintained.
• Immunological markers showed a decrease in activated T cells, an increase in B cells, and reduced anti-dsDNA antibody titers in most patients.

Conclusions:

• Mycophenolate mofetil is an effective option for maintenance therapy in lupus nephritis.
• A 3-month MMF regimen sustains the positive clinical and immunological outcomes achieved during induction therapy.
• MMF demonstrates a favorable safety profile for long-term lupus nephritis management.